PDS Biotechnology Corp
جودة البيانات: 83%
PDSB
NASDAQ
Manufacturing
Chemicals
KWD 1.17
▼
KWD 0.19
(-14.12%)
6 months return
—
Momentum
Neutral
ROE
-271.48%
النمو
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
الجودة
Return on Equity
-271.48%
أقل من متوسط القطاع (-54.68%)
ROIC-99.04%
Net MarginN/A
Op. MarginN/A
الأمان
Debt / Equity
N/A
Current Ratio2.09
Interest Coverage-5.91
التقييم
PE (TTM|NTM)
-1.76 | -2.53
أقل من متوسط القطاع (-1.50)
P/B Ratio6.41
EV/EBITDAN/A
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Negative free cash flow of -27.75 M
Price History
الاتجاهات المالية
السعر المستهدف للمحللين
3 محللين
Buy
+542.1%
upside to target
الحالي
KWD 1.17
Consensus Target
KWD 7.50
KWD 3.00
أدنى
KWD 15.00
أعلى
التوقعات
مكرر الربحية المستقبلي
-2.53
ربحية السهم المستقبلية
-KWD 0.54
الإيرادات المقدّرة
0.0
مفاجآت الأرباح
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -KWD 0.14
·
Rev Est: 0.0
| Q12025 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|
| Reported | -KWD 0.21 | -KWD 0.21 | -KWD 0.19 | -KWD 0.14 | — | — |
| Estimate | -KWD 0.25 | -KWD 0.23 | -KWD 0.20 | -KWD 0.20 | -KWD 0.14 | -KWD 0.15 |
| المفاجأة | +14.87% | +10.00% | +3.39% | +30.00% | — | — |
Growth
Rev 5Y: N/A · Earnings 1Y: N/A
Growth
Rev 5Y: N/A · Earnings 1Y: N/A| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
Profitability
ROE: -271.48% · Net Margin: N/A
Profitability
ROE: -271.48% · Net Margin: N/A| Revenue (TTM) | N/A | Net Income (TTM) | -34.50 M |
| ROE | -271.48% | ROA | -91.77% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -27.75 M |
| ROIC | -99.04% | FCF Growth (3Y) | N/A |
Safety
D/E: N/A · Current: 2.09
Safety
D/E: N/A · Current: 2.09| Debt / Equity | N/A | Current Ratio | 2.09 |
| Interest Coverage | -5.91 | Asset Turnover | N/A |
| Working Capital | 14.56 M | Tangible Book Value | 9.45 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: -1.76 · EV/EBITDA: N/A
Valuation
P/E: -1.76 · EV/EBITDA: N/A| P/E Ratio | -1.76 | Forward P/E | -2.53 |
| P/B Ratio | 6.41 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | N/A | Fwd Earnings Yield | N/A |
| FCF Yield | -45.83% | ||
| Market Cap | 60.56 M | Enterprise Value | 34.36 M |
Per Share
EPS: -0.74 · FCF/Share: -0.50
Per Share
EPS: -0.74 · FCF/Share: -0.50| EPS (Diluted TTM) | -0.74 | Revenue / Share | N/A |
| FCF / Share | -0.50 | OCF / Share | -0.50 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: 80.45% · CapEx/Rev: N/A
Efficiency
FCF Conv: 80.45% · CapEx/Rev: N/A| CapEx / Revenue | N/A | FCF Conversion | 80.45% |
| SBC-Adj. FCF | -32.48 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -34.50 M | -37.61 M | -42.94 M | -40.85 M | -16.92 M |
| EPS (Diluted) | -0.74 | -1.03 | -1.39 | -1.43 | -0.66 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -31.54 M | -36.32 M | -43.05 M | -41.67 M | -21.44 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 19.03 M | 22.57 M | 27.76 M | 29.43 M | 11.25 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | 5.34 M | 4.66 M | 4.21 M | 1.32 M | — |
| Income Tax | -1.17 M | -869,169.0 | -1.41 M | -1.20 M | -4.52 M |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 30.49 M | 45.36 M | 59.39 M | 77.01 M | 67.20 M |
| Total Liabilities | 21.24 M | 26.35 M | 33.26 M | 33.01 M | 3.99 M |
| Shareholders' Equity | 9.25 M | 19.00 M | 26.13 M | 44.00 M | 63.21 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 26.71 M | 41.69 M | 56.56 M | 73.82 M | 65.24 M |
| Current Assets | 28.25 M | 45.05 M | 59.06 M | 76.48 M | 66.84 M |
| Current Liabilities | 9.48 M | 17.09 M | 13.63 M | 9.82 M | 3.76 M |
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1605 نظير)
مقارنة بشركات مشابهة في Manufacturing
مقارنة الأقران
مقابل وسيط قطاع Manufacturing (1605 نظير) مقارنة بشركات مشابهة في Manufacturing| المقياس | السهم | وسيط القطاع |
|---|---|---|
| P/E | -1.8 | -1.5 |
| P/B | 6.4 | 1.6 |
| ROE % | -271.5 | -54.7 |
| Net Margin % | — | -41.5 |
| Rev Growth 5Y % | — | 1.7 |
| D/E | — | 0.3 |
{"event":"ticker_viewed","properties":{"ticker":"PDSB","listing_kind":"stock","pathname":"/stocks/pdsb","exchange":"NASDAQ","country":"US"}}